APOE ε4 and Alzheimer's disease diagnosis associated differences in L-carnitine, GBB, TMAO, and acylcarnitines in blood and brain - 03/02/23
Summary |
Background |
The apolipoprotein E (APOE) ε4 allele, involved in fatty acid (FA) metabolism, is a major genetic risk factor for Alzheimer's disease (AD). This study examined the influence of APOE genotypes on blood and brain markers of the L-carnitine system, necessary for fatty acid oxidation (FAO), and their collective influence on the clinical and pathological outcomes of AD.
Methods |
L-carnitine, its metabolites γ-butyrobetaine (GBB) and trimethylamine-n-oxide (TMAO), and its esters (acylcarnitines) were analyzed in blood from predominantly White community/clinic-based individuals (n = 372) and in plasma and brain from the Religious Order Study (ROS) (n = 79) using liquid chromatography tandem mass spectrometry (LC-MS/MS).
Findings |
Relative to total blood acylcarnitines, levels of short chain acylcarnitines (SCAs) were higher whereas long chain acylcarnitines (LCAs) were lower in AD, which was observed pre-clinically in APOE ε4s. Plasma medium chain acylcarnitines (MCAs) were higher amongst cognitively healthy APOE ε2 carriers relative to other genotypes. Compared to their respective controls, elevated TMAO and lower L-carnitine and GBB were associated with AD clinical diagnosis and these differences were detected preclinically among APOE ε4 carriers. Plasma and brain GBB, TMAO, and acylcarnitines were also associated with post-mortem brain amyloid, tau, and cerebrovascular pathologies.
Interpretation |
Alterations in blood L-carnitine, GBB, TMAO, and acylcarnitines occur early in clinical AD progression and are influenced by APOE genotype. These changes correlate with post-mortem brain AD and cerebrovascular pathologies. Additional studies are required to better understand the role of the FAO disturbances in AD.
Le texte complet de cet article est disponible en PDF.Keywords : Alzheimer's disease, APOE, Lipidomics, TMAO, GBB, L-carnitine, Acylcarnitines
Plan
Vol 71 - N° 1
Article 103362- janvier 2023 Retour au numéro
Article précédent
- Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome
- Junjie Cao, Renzhi Pei, Ying Lu, Zhongzheng Zheng, Zhiyang Yuan, Daiyang Li, Pisheng Zhang, Xuhui Liu, Dong Chen, Xiaohong Du, Lieguang Chen, Shuangyue Li, Peipei Ye, Tiantian Wang
- Cryopreserved allogeneic bone marrow mesenchymal stem cells show better osteochondral defect repair potential than adipose tissue mesenchymal stem cells
- Mudasir Bashir Gugjoo, Ejaz Rasool Dar, Fajar Farooq, Syed Mudasir Ahmad, Asif Hassan Sofi, Showkat Ahmad Shah, Mudasir Hamid Bhat, Tahir Ahmad Khan, Riaz Ahmad Shah, Jalal-ud-Din Parrah
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?